P38 map kinase inhibiting indanyl urea compounds

A Compound of formula (I)

• their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers, conformers, tautomers, polymorphs, hydrates, and solvates;
• wherein,
• Y is C═O or C(Z′);
• Q is C or N, when Y is C═O then Q is N;
• When Y is C═O, Z is selected from hydrogen, —(C1-C6)alkyl, branched-(C3-C6)alkyl, —(C3-C6)cycloalkyl, —(C1-C3)alkyl(C3-C6)cycloalkyl, —(C1-C6)alkyl-OH, —(C1-C6)alkyl-SH, —C(O)CH2R4, —(C1-C6)alkyl-NR5R6, —(C1-C6)alkyl-aryl, —(C1-C6)alkyl-heteroaryl, —(C1-C6)alkyl-CO2H, —(C1-C6)alkyl-CO2R7, —(C1-C6)alkyl-C(O)NR5R6, —C(O)NR5R6, —CO2R7, —COR7, —(C1-C6)alkyl-OR7, —(C1-C6)alkyl-S(O)nR7, —S(O)m—R7, —S(O)mN(R3)—R7, —S(O)mNR5R6, aryl and heteroaryl, wherein said aryl or heteroaryl may be further optionally substituted by 1-3 substituents independently selected from R8;
• or when Y is C(Z′), Z and Z′ together forms a 5 or 6 membered aromatic ring system having 1 to 3 heteroatoms independently selected from 0, S(O)n or N and the said ring is optionally substituted by 1-3 substituents independently selected from R8;
• P is a cyclic ring, which is selected from
• Where * denotes point of attachment to nitrogen;
• Ra, Rb, and Rc are independently selected from hydrogen, halogen, —(C1-C6)alkyl, branched-(C3-C6)alkyl, —(C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclic, —(C1-C6)alkyl-aryl, —(C1-C6)alkyl-heteroaryl, hydroxyl, —CF3, —OCF3, —NO2, —C(O)—(C1-C6)alkyl, —C(O)—(C3-C6)cycloalkyl, —C(O)CH2R4, —NR5R6, —N(R3)C(O)—R7, —N(R3)S(O)m—R7, —N(R3)C(O)—N(R3)—R7, —N(R3)C(S)N(R3)—R7, —OR7, —CO2H, —CO2R7, —C(O)—NR5R6, —SH, —S(O)a—R7, —S(O)mN(R3)—R7, —S(O)m—NR5R6, —CN, —CHO, —(C1-C6)alkyl-R4 and —(C1-C6)alkyl-NR5R6, wherein each aryl, heterocyclic or heteroaryl may be further optionally substituted with 1-3 substituents independently selected from halogen, —(C1-C6)alkyl, branched-(C3-C6)alkyl, aryl, heteroaryl, heterocyclic, hydroxyl, —CF3, —OCF3, —OR7, —O—(C1-C6)alkyl-R8, —NO2, —C(O)—(C1-C6)alkyl, —C(O)CH2R4, —NR5R6, —CO2H, —CO2R7, —C(O)NR5R6, —N(R3)C(O)—R7, —N(R3)S(O)m—R7, —SH, —S(O)a—R7, —S(O)mN(R3)—R7, —CN, —CHO, —(C1-C6)alkyl-OR7, —(C1-C6)alkyl-halogen and —(C1-C6)alkyl-NR5R6;
• or any two substituents of Ra, Rb, and Rc may form a saturated, partially saturated or unsaturated monocyclic ring, which may contain 0, 1, 2 or 3 ring heteroatoms selected from 0, S(O)n or N;
• W is —(CH2)t, —(CH2)mCO or —(CH2)mS(O)m;
• R is selected from hydrogen, —(C1-C6)alkyl, branched-(C3-C6)alkyl, halogen, —O(C1-C6)alkyl, —CF3, —OCF3 and hydroxyl;
• R1 and R2 are independently selected from hydrogen, hydroxyl, —(C1-C3)alkyl, branched-(C3-C6)alkyl and —(C3-C6)cycloalkyl or R1 and R2 together with the carbon to which they are attached, forms a —(C3-C6)cycloalkyl ring in a spiro manner;
• R3 is independently selected from hydrogen, —(C1-C3)alkyl, branched-(C3-C6)alkyl and —(C1-C3) alkyl(C3-C6) cycloalkyl, glucuronate;
• R4 is independently selected from hydroxyl, —SH, —OR7, —NR5R6, —S(O)n—R7, —S(O)n—(C1-C6)alkyl-CO2(C1-C6)alkyl, —S(O)n—(C1-C6)alkyl-OH, —S(O)n—(C1-C6)alkyl-CO2H, —N(R3)C(O)—R7, —N(R3)S(O)m—R7, —O—(C1-C6)alkyl-CO2(C1-C6)alkyl, —O—(C1-C6)alkyl-OH and —O—(C1-C6)alkyl-CO2H;
• R5 and R6 are independently selected from hydrogen, —(C1-C6)alkyl, branched-(C3-C6)alkyl, —COR7, —C(O)NR5R6, —S(O)mR7, —(C1-C6)alkyl-(C3-C6)cycloalkyl, —(C3-C6)cycloalkyl, aryl and heteroaryl or R5 and R6 are taken together with nitrogen to form a 3 to 8 membered monocyclic or 8 to 12 membered bicyclic heterocycle ring, wherein the said mono and bicyclic ring contain 0, 1, 2 or 3 ring heteroatoms selected from O, S(O)n or N and the said ring is optionally substituted by 1-3 substituents independently selected from R8;
• R7 is independently selected from —(C1-C6)alkyl, —(C1-C6)alkyl-OH, branched-(C3-C6)alkyl, —(C3-C6)cycloalkyl, —(C1-C6)alkyl-(C3-C6)cycloalkyl, aryl and heteroaryl;
• R8 is independently selected from hydrogen, halogen, hydroxyl, —CN, —CHO, —NO2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —(C1-C6)alkyl-(C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclic, —C(O)CH2R4, —OR7, —SH, —S(O)n—R7, —CF3, —OCF3, —CO2H, —COR7, —CO2R7, —C(O)NR5R6, —S(O)mN(R3)—R7 and —NR5R6, wherein the said (C1-C6)alkyl, aryl, heterocyclic and heteroaryl may be further substituted with 1-3 substituents independently selected from R9.
• R9 is independently selected from R7, halogen, hydroxyl, —(C1-C6)alkyl-OH, —NO2, —SH, —OR7, —OC(O)—R7, —O(C1-C6)alkyl-CO2R7, —O(C1-C6)alkyl-CO2H, —O(C1-C6)alkyl-C(O)—NR5R6, S(O)m—R7, —CO2R7, —CO2H, —C(O)—R7, —C(O)—NR5R6, —S(O)n—R7, —S(O)n(C1-C6)alkyl-R4, S(O)n(C1-C6)alkyl-C(O)NR5R6, —S(O)n(C1-C6)alkyl-CO2R7, —S(O)n(C1-C6)alkyl-CO2H, —NR5R6, —S(O)m—NR5R6, —N(R3)C(O)—R7, —N(R3)C(O)N(R3)—R7, —N(R3)C(S)N(R3)—R7, —N(R3)C(O)(C1-C6)alkyl-aryl, —N(R3)S(O)m—R7, OSO3H and O-glucuronate;
• m is 1 or 2;
• n is 0, 1 or 2;
• t is 2 or 3.